Celcuity Regulatory Tuesday, July 14, 2026 +0.80 Positive

Celcuity Announces FDA Approval for REVTORPYK for Breast Cancer

Celcuity announced FDA approval for the REVTORPYK targeted therapy to treat HR+/HER2- breast cancer without a PIK3CA mutation. The drug reduced the risk of disease progression or death by up to 76% in clinical trials.

View original filing at SEC.gov →

AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day